Sensei Biotherapeutics (NASDAQ:FTH) Earns Outperform Rating from Analysts at Citizens Jmp

Equities research analysts at Citizens Jmp initiated coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a report released on Monday. The firm set an “outperform” rating and a $51.00 price target on the stock. Citizens Jmp’s price objective would indicate a potential upside of 97.14% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. BTIG Research reiterated a “buy” rating and issued a $55.00 price target on shares of Sensei Biotherapeutics in a report on Thursday. Wall Street Zen cut Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Loop Capital set a $50.00 price target on Sensei Biotherapeutics in a research report on Thursday, May 28th. Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating for the company. Finally, Robert W. Baird started coverage on shares of Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.00.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ FTH opened at $25.87 on Monday. Sensei Biotherapeutics has a 52-week low of $6.32 and a 52-week high of $37.90. The company has a market cap of $34.67 million, a P/E ratio of -0.18 and a beta of -0.26.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. As a group, equities research analysts predict that Sensei Biotherapeutics will post -16.61 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder James Peyer sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider owned 130,142 shares in the company, valued at $2,605,442.84. This represents a 16.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the transaction, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This represents a 0.37% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 49,494 shares of company stock valued at $1,188,822 in the last 90 days. 7.00% of the stock is currently owned by insiders.

Institutional Trading of Sensei Biotherapeutics

A number of hedge funds have recently modified their holdings of FTH. Renaissance Technologies LLC lifted its position in Sensei Biotherapeutics by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after acquiring an additional 1,100 shares during the last quarter. Stempoint Capital LP bought a new position in shares of Sensei Biotherapeutics during the first quarter worth approximately $4,188,000. Bank of America Corp DE boosted its stake in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Finally, Vivo Capital LLC acquired a new position in Sensei Biotherapeutics in the 1st quarter valued at $22,758,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.